Rare disease therapies will dominate the market by growth, with a CAGR through 2023 of 119.6%, followed by ophthalmology at 53.5%. By size, the market will be led by neurology.

By delivery technology, market growth will be led by lentiviral vectors, with a CAGR of 131.5%, followed by AAV vectors, with a CAGR of 85.5%. By size, the market will be led by AAV vectors, with an estimated value of $6.2 billion. .

By platform technology, market growth will be led by gene therapy, with a CAGR through 2023 of 90.7%, followed by genetically modified cell therapy at 80.6%. By size, the segment will be led by gene therapy.

“Because of the potentially curative nature of these medicines there is enormous potential in many applications, ranging from cancer to neurology to rare diseases,” said BCC Research analyst and the report’s author John Bergin. “Genetic modification therapies represent the next wave of medicines with enormous potential for treating and curing debilitating and serious diseases. Because of its wide scope, genetic modification therapy will play an important role in the future global medical economy.”

Challenges Range from Delivery to Manufacturing

Each of the market’s approaches faces unique challenges, the report adds. For gene therapy and genetically modified cell therapy, those challenges are related to manufacturing, while delivery is the challenge to overcome for RNA therapy and safety and efficacy may restrain the gene editing field.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.